Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir.

AIDS research and human retroviruses - 1 Dec 2021

Wallner Jackson J, Beck Ingrid A, Panpradist Nuttada, Ruth Parker S, Valenzuela-Ponce Humberto, Soto-Nava Maribel, Ávila-Ríos Santiago, Lutz Barry R, Frenkel Lisa M

Abstract excerpt

The nucleoside reverse transcriptase inhibitor abacavir (ABC) is used commonly to treat young children with HIV infection and is a component of the fixed-dose-combination Triumeq®. ABC can trigger a severe hypersensitivity reaction in people who are homozygous or heterozygous for HLA-B*57:01. Testing for HLA-B*57:01 before ABC initiation is standard-of-care in high-resource settings, but current tests are costly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Dideoxynucleosides

Share to Genotype

Share to HIV Infections

Share to HLA-B Antigens

Share to Point-of-Care Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 34714103
DOI: 10.1089/AID.2021.0103
PMCID: PMC8716482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir.PMID 34714103Read ↗

Rapid, Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to AbacavirSemantic proximity Read ↗

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.Semantic proximity Read ↗

Novel Sensitive, Specific and Rapid Pharmacogenomic test for the Prediction of Abacavir Hypersensitivity Reaction: HLA-B*57:01 Detection by Real-Time PCRSemantic proximity Read ↗

Validation of two commercial real-time PCR assays for rapid screening of the HLA-B*57:01 allele in the HIV clinical laboratory.Semantic proximity Read ↗

Prevalence of HLA-B*57:01 and complete linkage disequilibrium with HCP5 rs2395029: Prevalence and DetectionSemantic proximity Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.Semantic proximity Read ↗

Development of HLA-B*57:01 Genotyping Real-Time PCR with Optimized Hydrolysis Probe Design.Semantic proximity Read ↗

Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.Semantic proximity Read ↗

Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity.Semantic proximity Read ↗

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.